The Israeli biotech company next year with start its late stage clinical trial of its therapy that modulates the immune system's response to the bacteria rather than attacking the bacteria itself
The Israeli biotech company next year with start its late stage clinical trial of its therapy that modulates the immune system's response to the bacteria rather than attacking the bacteria itself
Share this Article
Comment on this Article
Recommended
Please to comment